SCHEMBL5690501

SCHEMBL5690501

CC(Sc1ncc[nH]1)c1ccc(OC(=O)N2CCC(COc3ccc(C(=O)O)cc3)CC2)cc1

nearest known ligand 0.40

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 7/20 0.40
GPR88 Q9GZN0 1/20 0.40
CYP4F2 P78329 3/20 0.39
CYP4A11 Q02928 3/20 0.39
CHEK2 O96017 3/20 0.38
NPY2R P49146 1/20 0.36
PANK3 Q9H999 1/20 0.36
HSD11B1 P28845 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5931723 0.90 GPR88 (0.39) GPR119GPR88CYP4F2CYP4A11NPY2R
SCHEMBL5688003 0.88 SRD5A1 (0.46) GPR119CHEK2
SCHEMBL5931445 0.87 LIPE (0.41) GPR119GPR88CYP4F2CYP4A11NPY2R
SCHEMBL5689750 0.86 LIPE (0.45) GPR119GPR88CYP4F2CYP4A11
SCHEMBL5931586 0.85 HSD11B1 (0.42) GPR119NPY2RPANK3HSD11B1
SCHEMBL5690648 0.83 HSD11B1 (0.41) CYP4F2CYP4A11CHEK2HSD11B1
SCHEMBL5690401 0.83 NPC1 (0.36) GPR119GPR88CYP4F2CYP4A11PANK3
SCHEMBL5691711 0.83 HSD11B1 (0.35) GPR119GPR88CYP4F2CYP4A11PANK3
SCHEMBL5687404 0.82 HSD11B1 (0.44) CYP4F2CYP4A11CHEK2HSD11B1
SCHEMBL5931747 0.82 MGLL (0.38) NPY2RPANK3HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160851-A1 Substituted piperidine carbamates LIPE, PNLIP, LIPC GPR119 50/4885GPR88 1293/4885CYP4F2 2649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.